Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial (Q51816015)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 August 2009

Language	Label	Description	Also known as
English	Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial	scientific article published on 7 August 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

object named as

Matthew Links

15

0 references

object named as

Peter Gibbs

14

0 references

7

object named as

John R Zalcberg

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

author name string

Nicole Mittmann

1

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Heather-Jane Au

2

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Dongsheng Tu

3

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Christopher J O'Callaghan

4

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Pierre K Isogai

5

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Christos S Karapetis

6

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

William K Evans

8

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Malcolm J Moore

9

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Jehan Siddiqui

10

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Brian Findlay

11

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Bruce Colwell

12

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

John Simes

13

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Niall C Tebbutt

16

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Derek J Jonker

17

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group

18

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Australasian Gastrointestinal Interest Group

19

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

language of work or name

0 references

publication date

7 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

101

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

17

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

1182-1192

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Multi-attribute preference functions. Health Utilities Index

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Quality of life in survivors of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Whose utilities for decision analysis?

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Assessing the appropriateness of combining economic data from multinational clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Projections of the costs associated with colorectal cancer care in the United States, 2000-2020.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Evaluation of trends in the cost of initial cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

The price tag on progress--chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Expensive cancer drugs with modest benefit ignite debate over solutions

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

National Institute for Clinical Excellence and its value judgments

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Do oncologists believe new cancer drugs offer good value?

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP232

21 January 2018

Identifiers

10.1093/JNCI/DJP232

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19666851

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51816015&oldid=2283247260"